halcinonide Indications/Contra | FAERs | Orange Book | BioActivity |

Stem definitionDrug idCAS RN
steroids for topical use, acetal derivatives 4507 3093-35-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • halcinonide
  • alcinonide
  • halciderm
  • halcimat
  • halog
A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.
  • Molecular weight: 454.96
  • Formula: C24H32ClFO5
  • CLOGP: 3.31
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.83
  • ALOGS: -4.61
  • ROTB: 2

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Nov. 27, 1974 FDA RANBAXY

FDA Adverse Event Reporting System

None

Pharmacologic Action:

SourceCodeDescription
ATC D07AD02 DERMATOLOGICALS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
CORTICOSTEROIDS, PLAIN
Corticosteroids, very potent (group IV)
MeSH PA D000893 Anti-Inflammatory Agents
FDA EPC N0000175576 Corticosteroid
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Primary cutaneous T-cell lymphoma indication 400122007
Glaucoma contraindication 23986001 DOID:1686
Diabetes mellitus type 2 contraindication 44054006 DOID:9352
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Tuberculosis of skin contraindication 66986005
Bilateral cataracts contraindication 95722004
Atrophoderma contraindication 399979006 DOID:2733
Peripheral vascular disease contraindication 400047006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.17 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST Ki 9.14 DRUG MATRIX CHEMBL
Androgen receptor Transcription factor Ki 6.23 DRUG MATRIX
Progesterone receptor Transcription factor Ki 9.92 DRUG MATRIX

External reference:

IDSource
D01308 KEGG_DRUG
4017606 VUID
N0000145986 NUI
C0018513 UMLSCUI
CHEMBL1200845 ChEMBL_ID
D006206 MESH_DESCRIPTOR_UI
DB06786 DRUGBANK_ID
SI86V6QNEG UNII
3392 INN_ID
5084 RXNORM
29058003 SNOMEDCT_US
395735005 SNOMEDCT_US
4814 MMSL
4017606 VANDF
N0000005987 NDFRT
N0000145986 NDFRT
002200 NDDF
443943 PUBCHEM_CID
CHEBI:31663 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Halog HUMAN PRESCRIPTION DRUG LABEL 1 10631-094 CREAM 1 mg TOPICAL NDA 11 sections
HALOG HUMAN PRESCRIPTION DRUG LABEL 1 10631-096 OINTMENT 1 mg TOPICAL NDA 10 sections